Relevance of rituximab therapy in pemphigus vulgaris: Analysis of current data and the immunologic basis for its observed responses

Expert Review of Clinical Immunology

Volumn 7, Issue 4, 2011, Pages 529-541

  Feldman, Ron J ^a   Ahmed, A Razzaque ^a  

^a Center for Blistering Diseases   (United States)

Author keywords

B lymphocyte; conventional immunosuppressive therapies; intravenous immunoglobulin; pemphigus; rituximab

Indexed keywords

B LYMPHOCYTE RECEPTOR; CD16 ANTIGEN; CD19 ANTIGEN; CD20 ANTIBODY; CD24 ANTIGEN; CD27 ANTIGEN; CD34 ANTIBODY; CD38 ANTIGEN; CD5 ANTIGEN; COMMON ACUTE LYMPHOBLASTIC LEUKEMIA ANTIGEN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DEXAMETHASONE; IMMUNOGLOBULIN A; IMMUNOGLOBULIN D; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; IMMUNOSUPPRESSIVE AGENT; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RITUXIMAB; SYNDECAN 1;

ADJUVANT THERAPY; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; B LYMPHOCYTE; BACTERIAL ARTHRITIS; BREAST FEEDING; CD4 LYMPHOCYTE COUNT; CELL FUNCTION; CELL MATURATION; CELL POPULATION; CHILL; CLINICAL PROTOCOL; COMMUNITY ACQUIRED PNEUMONIA; COMPLEMENT DEPENDENT CYTOTOXICITY; COMPLETE REMISSION; CYTOLOGY; CYTOMEGALOVIRUS GASTRITIS; CYTOMEGALOVIRUS RETINITIS; DEEP VEIN THROMBOSIS; DISEASE ASSOCIATION; DNA POLYMORPHISM; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG FATALITY; DRUG MECHANISM; DRUG WITHDRAWAL; FEVER; FOLLOW UP; HEADACHE; HEART DISEASE; HEPATITIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOGLOBULIN DEFICIENCY; INCIDENCE; INFECTION; LATE ONSET NEUTROPENIA; LOW DRUG DOSE; LUNG EMBOLISM; MAJOR HISTOCOMPATIBILITY COMPLEX; MEMORY CELL; META ANALYSIS; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; PARTIAL REMISSION; PEMPHIGUS VULGARIS; PNEUMOCYSTIS PNEUMONIA; PNEUMONIA; PREGNANCY; PRURITUS; PYELONEPHRITIS; RASH; RECURRENT DISEASE; REMISSION; REVIEW; SENSITIZATION; SEPSIS; SERUM SICKNESS; SINGLE DRUG DOSE; STEVENS JOHNSON SYNDROME; THERAPY EFFECT; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT RESPONSE; URTICARIA; VASCULITIS;

ANIMALS; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; AUTOIMMUNITY; B-LYMPHOCYTES; CLINICAL PROTOCOLS; HUMANS; IMMUNOSUPPRESSION; IMMUNOTHERAPY; LYMPHOCYTE DEPLETION; MONITORING, PHYSIOLOGIC; PEMPHIGUS; SKIN;

EID: 79960902208     PISSN: 1744666X     EISSN: 17448409     Source Type: Journal    
DOI: 10.1586/eci.11.22     Document Type: Review

References (92)

1. Nousari HC, Anhalt GJ. Pemphigus and bullous pemphigoid. Lancet 354(9179), 667-672 (1999) (Pubitemid 29391440)
2. Scott JE, Ahmed AR. The blistering diseases. Med Clin North Am. 82(6), 1239-1283 (1998) (Pubitemid 28512423)
3. Korman NJ. Pemphigus. Dermatol. Clin 8(4), 689-700 (1990)
4. Meurer M, Millns JL, Rogers RS 3rd, Jordon RE. Oral pemphigus vulgaris. A report of ten cases. Arch Dermatol. 113(11), 1520-1524 (1977) (Pubitemid 8232735)
5. Yeh SW, Sami N, Ahmed RA. Treatment of pemphigus vulgaris: current and emerging options. Am J Clin Dermatol. 6(5), 327-342 (2005) (Pubitemid 41577407)
6. Pisanti S, Sharav Y, Kaufman E, Posner LN. Pemphigus vulgaris: incidence in Jews of different ethnic groups, according to age, sex, and initial lesion. Oral Surg. Oral Med. Oral Pathol. 38(3), 382-387 (1974)
7. Toth GG, Jonkman MF. Therapy of pemphigus. Clin Dermatol. 19(6), 761-767 (2001) (Pubitemid 33036851)
8. Savin JA. The events leading to the death of patients with pemphigus and pemphigoid. Br J. Dermatol. 101(5), 521-534 (1979) (Pubitemid 10132177)
9. Ahmed AR, Moy R. Death in pemphigus. J Am Acad. Dermatol. 7(2), 221-228 (1982) (Pubitemid 12092372)
10. Levesque MC. Translational mini-review series on B cell-directed therapies: recent advances in B cell-directed biological therapies for autoimmune disorders. Clin Exp. Immunol. 157(2), 198-208 (2009)
11. Levesque MC, St Clair EW. B cell-directed therapies for autoimmune disease and correlates of disease response and relapse. J Allergy Clin. Immunol. 121(1), 13-21; quiz 22-13 (2008)
12. Cartron G, Watier H, Golay J, Solal-Celigny P. From the bench to the bedside: ways to improve rituximab efficacy. Blood 104(9), 2635-2642 (2004) (Pubitemid 39434941)
13. Winiarska M, Bil J, Wilczek E et al. Statins impair antitumor effects of rituximab by inducing conformational changes of CD20. PLoS Med. 5(3), e64 (2008)
14. Binder M, Otto F, Mertelsmann R, Veelken H, Trepel M. The epitope recognized by rituximab. Blood 108(6), 1975-1978 (2006) (Pubitemid 44395009)
15. Kneitz C, Wilhelm M, Tony HP. Effective B cell depletion with rituximab in the treatment of autoimmune diseases. Immunobiology 206(5), 519-527 (2002) (Pubitemid 36192911)
16. Pers JO, Devauchelle V, Daridon C et al. BAFF-modulated repopulation of B lymphocytes in the blood and salivary glands of rituximab-treated patients with Sjogrens syndrome. Arthritis Rheum. 56(5), 1464-1477 (2007) (Pubitemid 46764075)
17. Teng YK, Levarht EW, Hashemi M et al. Immunohistochemical analysis as a means to predict responsiveness to rituximab treatment. Arthritis Rheum. 56(12), 3909-3918 (2007) (Pubitemid 350262317)
18. Smith MR. Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance. Oncogene 22(47), 7359-7368 (2003)
19. Lim SH, Beers SA, French RR, Johnson PW, Glennie MJ, Cragg MS. Anti-CD20 monoclonal antibodies: historical and future perspectives. Haematologica 95(1), 135-143 (2010)
20. Cartron G, Dacheux L, Salles G et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgRIIIa gene. Blood 99(3), 754-758 (2002) (Pubitemid 34525533)
21. Hertl M, Zillikens D, Borradori L et al. Recommendations for the use of rituximab (anti-CD20 antibody) in the treatment of autoimmune bullous skin diseases. J Dtsch. Dermatol. Ges. 6(5), 366-373 (2008)
22. Maloney DG, Grillo-Lopez AJ, White CA et al. IDEC-C2B8 (rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkins lymphoma. Blood 90(6), 2188-2195 (1997) (Pubitemid 27392702)
23. Ahmed AR, Spigelman Z, Cavacini LA, Posner MR. Treatment of pemphigus vulgaris with rituximab and intravenous immune globulin. N Engl J. Med 355(17), 1772-1779 (2006) (Pubitemid 44631360)
24. Ahmed AR, Dahl MV. Consensus statement on the use of intravenous immunoglobulin therapy in the treatment of autoimmune mucocutaneous blistering diseases. Arch Dermatol. 139(8), 1051-1059 (2003) (Pubitemid 36994832)
25. Schmidt E, Goebeler M, Zillikens D. Rituximab in severe pemphigus. Ann NY Acad. Sci. 1173, 683-691 (2009)
26. Antonucci A, Negosanti M, Tabanelli M, Varotti C. Treatment of refractory pemphigus vulgaris with anti-CD20 monoclonal antibody (rituximab): five cases. J Dermatolog. Treat. 18(3), 178-183 (2007) (Pubitemid 46854827)
27. Arin MJ, Engert A, Krieg T, Hunzelmann N. Anti-CD20 monoclonal antibody (rituximab) in the treatment of pemphigus. Br J. Dermatol. 153(3), 620-625 (2005) (Pubitemid 41248223)
28. Barrera MV, Mendiola MV, Bosch RJ, Herrera E. Prolonged treatment with rituximab in patients with refractory pemphigus vulgaris. J Dermatolog. Treat. 18(5), 312-314 (2007) (Pubitemid 47537257)
29. Belgi AS, Azeez M, Hoyle C, Williams RE. Response of pemphigus vulgaris to anti-CD20 antibody therapy (rituximab) may be delayed. Clin Exp. Dermatol. 31(1),(2006)
30. Cecchi R, Gasperini U. Severe pemphigus vulgaris treated with rituximab (Mabthera). J Dermatol. 32(10), 862-864 (2005) (Pubitemid 41703770)
31. Cianchini G, Corona R, Frezzolini A, Ruffelli M, Didona B, Puddu P. Treatment of severe pemphigus with rituximab: report of 12 cases and a review of the literature. Arch Dermatol. 143(8), 1033-1038 (2007) (Pubitemid 47296080)
32. Cooper HL, Healy E, Theaker JM, Friedmann PS. Treatment of resistant pemphigus vulgaris with an anti-CD20 monoclonal antibody (rituximab). Clin Exp. Dermatol. 28(4), 366-368 (2003) (Pubitemid 36801837)
33. Dupuy A, Viguier M, Bedane C et al. Treatment of refractory pemphigus vulgaris with rituximab (anti-CD20 monoclonal antibody). Arch Dermatol. 140(1), 91-96 (2004) (Pubitemid 38090275)
34. Eming R, Nagel A, Wolff-Franke S, Podstawa E, Debus D, Hertl M. Rituximab exerts a dual effect in pemphigus vulgaris. J Invest. Dermatol. 128(12), 2850-2858 (2008)
35. Espana A, Fernandez-Galar M, Lloret P, Sanchez-Ibarrola A, Panizo C. Long-term complete remission of severe pemphigus vulgaris with monoclonal anti-CD20 antibody therapy and immunophenotype correlations. J Am Acad. Dermatol. 50(6), 974-976 (2004) (Pubitemid 38685787)
36. Eming R, Nagel A, Wolff-Franke S, Podstawa E, Debus D, Hertl M. Rituximab exerts a dual effect in pemphigus vulgaris. J Invest. Dermatol. 128(12), 2850-2858 (2008)
37. Faurschou A, Gniadecki R. Two courses of rituximab (anti-CD20 monoclonal antibody) for recalcitrant pemphigus vulgaris. Int. J Dermatol. 47(3), 292-294 (2008) (Pubitemid 351266854)
38. Fuertes I, Guilabert A, Mascaro JM Jr, Iranzo P. Rituximab in childhood pemphigus vulgaris: a long-term follow-up case and review of the literature. Dermatology 221(1), 13-16 (2010)
39. Goh MS, McCormack C, Dinh HV, Welsh B, Foley P, Prince HM. Rituximab in the adjuvant treatment of pemphigus vulgaris: a prospective open-label pilot study in five patients. Br J. Dermatol. 156(5), 990-996 (2007) (Pubitemid 46642840)
40. Herrmann G, Hunzelmann N, Engert A. Treatment of pemphigus vulgaris with anti-CD20 monoclonal antibody (rituximab). Br J. Dermatol. 148(3), 602-603 (2003) (Pubitemid 36461354)
41. Joly P, Mouquet H, Roujeau JC et al. A single cycle of rituximab for the treatment of severe pemphigus. N Engl J. Med 357(6), 545-552 (2007) (Pubitemid 47236279)
42. Kong HH, Prose NS, Ware RE, Hall RP 3rd. Successful treatment of refractory childhood pemphgus vulgaris with anti-CD20 monoclonal antibody (rituximab). Pediatr. Dermatol. 22(5), 461-464 (2005) (Pubitemid 43961007)
43. Mamelak AJ, Eid MP, Cohen BA, Anhalt GJ. Rituximab therapy in severe juvenile pemphigus vulgaris. Cutis 80(4), 335-340 (2007)
44. Marker M, Derfler K, Monshi B, Rappersberger K. Successful immunoapheresis of bullous autoimmune diseases: pemphigus vulgaris and pemphigoid gestationis. J Dtsch Dermatol. Ges. 9(1), 27-31 (2011)
45. Marzano AV, Fanoni D, Venegoni L, Berti E, Caputo R. Treatment of refractory pemphigus with the anti-CD20 monoclonal antibody (rituximab). Dermatology 214(4), 310-318 (2007) (Pubitemid 46659013)
46. Morrison LH. Therapy of refractory pemphigus vulgaris with monoclonal anti-CD20 antibody (rituximab). J Am Acad. Dermatol. 51(5), 817-819 (2004) (Pubitemid 39516904)
47. Mouquet H, Musette P, Gougeon ML et al. B-cell depletion immunotherapy in pemphigus: effects on cellular and humoral immune responses. J Invest. Dermatol. 128(12), 2859-2869 (2008)
48. Muller R, Hunzelmann N, Baur V et al. Targeted immunotherapy with rituximab leads to a transient alteration of the IgG autoantibody profile in pemphigus vulgaris. Dermatol. Res. Pract. 2010, 321950 (2010)
49. Nagel A, Podstawa E, Eickmann M, Muller HH, Hertl M, Eming R. Rituximab mediates a strong elevation of B-cellactivating factor associated with increased pathogen-specific IgG but not autoantibodies in pemphigus vulgaris. J Invest. Dermatol. 129(9), 2202-2210 (2009)
50. Niedermeier A, Worl P, Barth S, Schuler G, Hertl M. Delayed response of oral pemphigus vulgaris to rituximab treatment. Eur. J Dermatol. 16(3), 266-270 (2006) (Pubitemid 43736147)
51. Pfutze M, Eming R, Kneisel A, Kuhlmann U, Hoyer J, Hertl M. Clinical and immunological follow-up of pemphigus patients on adjuvant treatment with immunoadsorption or rituximab. Dermatology 218(3), 237-245 (2009)
52. Salopek TG, Logsetty S, Tredget EE. Anti-CD20 chimeric monoclonal antibody (rituximab) for the treatment of recalcitrant, life-threatening pemphigus vulgaris with implications in the pathogenesis of the disorder. J Am Acad. Dermatol. 47(5), 785-788 (2002) (Pubitemid 35239347)
53. Schmidt E, Herzog S, Brocker EB, Zillikens D, Goebeler M. Long-standing remission of recalcitrant juvenile pemphigus vulgaris after adjuvant therapy with rituximab. Br J. Dermatol. 153(2), 449-451 (2005) (Pubitemid 41228455)
54. Schmidt E, Seitz CS, Benoit S, Brocker EB, Goebeler M. Rituximab in autoimmune bullous diseases: mixed responses and adverse effects. Br J. Dermatol. 156(2), 352-356 (2007) (Pubitemid 46095965)
55. Shimanovich I, Nitschke M, Rose C, Grabbe J, Zillikens D. Treatment of severe pemphigus with protein A immunoadsorption, rituximab and intravenous immunoglobulins. Br J. Dermatol. 158(2), 382-388 (2008)
56. Sorce M, Arico M, Bongiorno MR. Rituximab in refractory pemphigus vulgaris. Dermatol. Ther. 21(Suppl. 1), S6-S9 (2008) (Pubitemid 352033054)
57. Strowd LC, Taylor SL, Jorizzo JL, Namazi MR. Therapeutic ladder for pemphigus vulgaris: emphasis on achieving complete remission. J Am Acad. Dermatol. 64(3), 490-494 (2011)
58. Virgolini L, Marzocchi V. Anti-CD20 monoclonal antibody (rituximab) in the treatment of autoimmune diseases. Successful result in refractory pemphigus vulgaris: report of a case. Haematologica 88(7), ELT24 (2003)
59. Weger W, Aberer E. Treatment failure with rituximab in a patient with pemphigus vulgaris. J Eur. Acad. Dermatol. Venereol. 22(3), 387-389 (2008) (Pubitemid 351247446)
60. Wenzel J, Bauer R, Bieber T, Tuting T. Successful rituximab treatment of severe pemphigus vulgaris resistant to multiple immunosuppressants. Acta Derm. Venereol. 85(2), 185-186 (2005) (Pubitemid 40477679)
61. Leuci S, Levine D, Zhang J, Razzaque Ahmed A. Response in patients with pemphigus vulgaris to rituximab therapy. Basis of the biology of B cell. G. Ital. Dermatol. Venereol. 144(4), 379-409 (2009)
62. Murrell DF, Dick S, Ahmed AR et al. Consensus statement on definitions of disease, end points, and therapeutic response for pemphigus. J Am Acad. Dermatol. 58(6), 1043-1046 (2008)
63. Schmidt E, Hennig K, Mengede C, Zillikens D, Kromminga A. Immunogenicity of rituximab in patients with severe pemphigus. Clin Immunol. 132(3), 334-341 (2009)
64. Vogel WH. Infusion reactions: diagnosis, assessment, and management. Clin J. Oncol. Nurs. 14(2), E10-E21 (2010)
65. Dereure O, Navarro R, Rossi JF, Guilhou JJ. Rituximab-induced vasculitis. Dermatology 203(1), 83-84 (2001)
66. Herishanu Y. Rituximab-induced serum sickness. Am J Hematol. 70(4), 329 (2002)
67. Lowndes S, Darby A, Mead G, Lister A. Stevens-Johnson syndrome after treatment with rituximab. Ann Oncol. 13(12), 1948-1950 (2002) (Pubitemid 36040785)
68. Voog E, Morschhauser F, Solal-Celigny P. Neutropenia in patients treated with rituximab. N Engl J. Med 348(26), 2691-2694; discussion 2691-2694 (2003)
69. Wolach O, Bairey O, Lahav M. Lateonset neutropenia after rituximab treatment: case series and comprehensive review of the literature. Medicine (Baltimore), 89(5), 308-318 (2010)
70. Li SC, Chen YC, Evens AM et al. Rituximab-induced late-onset neutropenia in newly diagnosed B-cell lymphoma correlates with Fc receptor FcgRIIIa 158(V/F) polymorphism. Am J Hematol. 85(10), 810-812 (2010)
71. Cambridge G, Leandro MJ, Edwards JC et al. Serologic changes following B lymphocyte depletion therapy for rheumatoid arthritis. Arthritis Rheum. 48(8), 2146-2154 (2003) (Pubitemid 36959194)
72. Radbruch A, Muehlinghaus G, Luger EO et al. Competence and competition: the challenge of becoming a long-lived plasma cell. Nat Rev. Immunol. 6(10), 741-750 (2006) (Pubitemid 44453460)
73. LeBien TW, Tedder TF. B lymphocytes: how they develop and function. Blood 112(5), 1570-1580 (2008)
74. Hoyer BF, Manz RA, Radbruch A, Hiepe F. Long-lived plasma cells and their contribution to autoimmunity. Ann NY Acad. Sci. 1050, 124-133 (2005) (Pubitemid 41129429)
75. Anderson SM, Tomayko MM, Shlomchik MJ. Intrinsic properties of human and murine memory B cell. Immunol. Rev. 211, 280-294 (2006) (Pubitemid 43882979)
76. Weller S, Braun MC, Tan BK et al. Human blood IgM "memory" B cell are circulating splenic marginal zone B cell harboring a prediversified immunoglobulin repertoire. Blood 104(12), 3647-3654 (2004) (Pubitemid 39564441)
77. Oracki SA, Walker JA, Hibbs ML, Corcoran LM, Tarlinton DM. Plasma cell development and survival. Immunol. Rev. 237(1), 140-159)
78. Kruetzmann S, Rosado MM, Weber H et al. Human immunoglobulin M memory B cell controlling Streptococcus pneumoniae infections are generated in the spleen. J Exp. Med 197(7), 939-945 (2003) (Pubitemid 36437871)
79. Looney RJ, Srinivasan R, Calabrese LH. The effects of rituximab on immunocompetency in patients with autoimmune disease. Arthritis Rheum. 58(1), 5-14 (2008)
80. Lu TY, Ng KP, Cambridge G et al. A retrospective seven-year analysis of the use of B cell depletion therapy in systemic lupus erythematosus at University College London Hospital: the first fifty patients. Arthritis Rheum. 61(4), 482-487 (2009)
81. Roll P, Palanichamy A, Kneitz C, Dorner T, Tony HP. Regeneration of B cell subsets after transient B cell depletion using anti-CD20 antibodies in rheumatoid arthritis. Arthritis Rheum. 54(8), 2377-2386 (2006) (Pubitemid 44204997)
82. Vital EM, Dass S, Rawstron AC et al. Management of nonresponse to rituximab in rheumatoid arthritis: predictors and outcome of re-treatment. Arthritis Rheum. 62(5), 1273-1279 (2010)
83. Vidal L, Gafter-Gvili A, Leibovici L et al. Rituximab maintenance for the treatment of patients with follicular lymphoma: systematic review and meta-analysis of randomized trials. J Natl Cancer Inst. 101(4), 248-255 (2009)
84. Looney RJ, Anolik JH, Campbell D et al. B cell depletion as a novel treatment for systemic lupus erythematosus: a Phase I/II dose-escalation trial of rituximab. Arthritis Rheum. 50(8), 2580-2589 (2004) (Pubitemid 39062719)
85. Maeda T, Yamada Y, Tawara M et al. Successful treatment with a chimeric anti-CD20 monoclonal antibody (IDECC2B8, rituximab) for a patient with relapsed mantle cell lymphoma who developed a human anti-chimeric antibody. Int. J Hematol. 74(1), 70-75 (2001) (Pubitemid 33798754)
86. Leandro MJ, Cambridge G, Ehrenstein MR, Edwards JC. Reconstitution of peripheral blood B cell after depletion with rituximab in patients with rheumatoid arthritis. Arthritis Rheum. 54(2), 613-620 (2006) (Pubitemid 43228639)
87. Roll P, Dorner T, Tony HP. Anti-CD20 therapy in patients with rheumatoid arthritis: predictors of response and B cell subset regeneration after repeated treatment. Arthritis Rheum. 58(6), 1566-1575 (2008) (Pubitemid 351847509)
88. Bystryn JC, Steinman NM. The adjuvant therapy of pemphigus. An update. Arch Dermatol. 132(2), 203-212 (1996)
89. Mignogna MD, Lo Muzio L, Ruocco E. Pemphigus induction by influenza vaccination. Int. J Dermatol. 39(10), 800 (2000)
90. De Simone C, Caldarola G, DAgostino M, Zampetti A, Amerio P, Feliciani C. Exacerbation of pemphigus after influenza vaccination. Clin Exp. Dermatol. 33(6), 718-720 (2008)
91. Adam Z, Krejci M, Pour L, Feit J, Buchler T, Hajek R. IgA pemphigus associated with monoclonal gammopathy completely resolved after achievement of complete remission of multiple myeloma with bortezomib, cyclophosphamide and dexamethasone regimen. Wien Klin Wochenschr. 122(9-10), 311-314 (2010)
92. Arthritis and influenza update 2010-2011 www.cdc.gov/arthritis/flu.htm